Physician profile
Mary Lilko
NPI 1902808983
$436.28
in general payments reported to CMS, 2019-2025
13 companies · $45.69 in 2025
The $45.69 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91.69 · 2020: $13.88 · 2021: $64.62 · 2022: $14.09 · 2023: $76.43 · 2024: $130 · 2025: $45.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $252.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $93.76 | 2021-2024 | Trelegy Ellipta |
| Boston Scientific Corporation | $90.28 | 2023-2024 | Watchman Flx |
| Lilly USA, LLC | $52.58 | 2023-2024 | Mounjaro, Zepbound |
| Novo Nordisk INC | $44.39 | 2019-2022 | |
| Exact Sciences Corporation | $31.81 | 2025 | The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $23.71 | 2019 | |
| Medtronic, INC. | $21.82 | 2024 | Intellis Adaptivestim |
| Amarin Pharma, INC. | $15.35 | 2019 | |
| Amgen INC. | $13.88 | 2025 | Repatha, Otezla |
| Teva Pharmaceuticals USA, INC. | $13.86 | 2019 | |
| Abbott Laboratories | $12.49 | 2021 | |
| Philips North America LLC | $11.45 | 2019 | |
| Pfizer INC. | $10.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Lilko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.